Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYL1801 dose-finding in neovascular (wet) age-related macular degeneration
2022-000214-34Phase 2Completed
- Sponsor
- Sylentis
- Start
- Jun 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SYL1801 in age-related macular degeneration (AMD) (3 arms), sponsored by Sylentis. Primary endpoint: Visual acuity change. Started Jun 2022; status: completed.
02
Drugs
SYL1801
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2022-000214-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000214-34.